Patients may be directed to receive their infused therapy from a physician’s office or infusion center rather than a hospital outpatient clinic due to a cost differential. Studies demonstrate that costs are substantially higher when infusions are delivered in a hospital outpatient setting, with no difference in quality of care.
- Hayes J, Hoverman JR, Brow ME, et al. Cost differential by site of service for cancer patients receiving chemotherapy.Am J Manag Care. 2015;21(3):e189-e196.
- Community Oncology Alliance. 2018 Community Oncology Alliance Practice Impact Report. 2018. https://www.communityoncology.org/wp-content/uploads/sites/20/2018/06/COA-Practice-Impact-Report-2018-FINAL.pdf. Accessed November 19, 2018.
- Hopson S, Casebeer A, Stemkowski S, et al. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States?J Med Econ. 2018;21(2):152-262.
- Fisher MD, Punekar R, Yim YM, et al. Differences in health care use and costs among patients with cancer receiving intravenous chemotherapy in physician offices versus in hospital outpatient settings. J Oncol Pract. 2017;13(1):e37-e46.
- Higgins A, Veselovskiy G, Schinkel J. National estimates of price variation by site of care. Am J Manag Care. 2016;22(3):e116-e121.
- Macher D. Payer Trends in Oncology. Avalere Health. 2018. http://avalere.com/expertise/life-sciences/insights/payer-trends-in-oncology. Accessed November 19, 2018.
- Centers of Medicare and Medicaid Services. Medicare program: proposed changes to hospital outpatient prospective payment and ambulatory surgical center payment systems and quality reporting programs; requests for information on promoting interoperability and electronic health care information, price transparency, and leveraging authority for the competitive acquisition program for part B drugs and biologicals for a potential CMS innovation center model. Fed Regist. 2018;83(147):37046-37240. Codified at 42 CFR 416-419.